SK pharmteco Invests $260 Million to Expand Small Molecule and Peptide Production
Monday, September 30, 2024
SK pharmteco has revealed a significant investment of $260 million to enhance its small molecule and peptide production capabilities.
This new facility represents a significant investment in SK pharmteco's future and reinforces its commitment to delivering exceptional value to customers.
This expansion will involve the construction of a new, state-of-the-art facility in Sejong, South Korea, which is set to begin operations in late 2026.
This new facility will be the fifth plant established by SK pharmteco in South Korea and will play a vital role in the company’s global manufacturing network. Covering 135,800 square feet, it will feature eight production trains with an annual output capacity of several metric tons.
Additionally, the facility will include advanced peptide research and development areas, CGMP kilo labs, and a CGMP pilot plant specifically for peptide manufacturing. These resources will support both early-stage clinical and commercial production with considerable flexibility.
The investment will also lay the groundwork for a sixth manufacturing plant, allowing for swift capacity expansion in the future.
The expansion demonstrates SK pharmteco's commitment to meeting the evolving needs of the life sciences sector. By increasing capacity in Asia, the company aims to enhance its global expansion strategy and strengthen its reputation as a reliable partner for organisations developing innovative treatments.
As part of this expansion, SK pharmteco plans to create over 300 new jobs at the Sejong facility. This investment highlights the company’s dedication to addressing the rising demand for high-quality peptides and small molecules, which are crucial components of many groundbreaking therapies.
The life sciences industry is experiencing rapid growth, driven by technological advancements and an increasing demand for innovative treatments. However, the global supply chain for these therapies faces challenges, including limited manufacturing capacity and complex regulatory requirements.
SK pharmteco’s new facility aims to address these issues by offering a scalable and dependable solution for the production of essential therapies.
By expanding its capacity and capabilities, the company aims to provide faster turnaround times, greater flexibility, and improved quality, further solidifying its position as a trusted partner for organisations involved in developing innovative cell and gene therapies, as well as small molecules.
Source: skpharmteco.com
